ELV

Business profile & competitive position

Elevance Health is a large U.S. managed-care company operating within the Healthcare sector under the Medical – Healthcare Plans industry classification. According to its most recent 10-K filing, the company served approximately 45.2 million medical members through affiliated health plans as of December 31, 2025. Its core activity is selling network-based, risk-based managed care plans to the Individual, Employer Group, Medicaid and Medicare markets, while also providing fee-based administrative services to self-funded employers and earning pharmacy and health-service fees through its Carelon businesses. The company reports four segments: Health Benefits, CarelonRx, CarelonServices and Corporate & Other.

The reported financial shape of the franchise is consistent with an insurer operating at scale rather than a high-margin service business. The trailing net margin is 2.5%, which is typical for managed-care plans because premiums collected are mostly paid back out as medical claims. ROE comes in at 11.6%, suggesting the company is still translating its membership base into a modest but durable return on shareholder equity. Its identity as an independent Blue Cross and Blue Shield Association licensee in 14 states/territories under the Anthem Blue Cross and Anthem Blue Cross and Blue Shield brands provides brand recognition and local market access, though it also ties Elevance to the pricing and regulatory environment faced by the broader Blue system.

Financial posture

Elevance currently carries a market capitalization of $93.6 billion and trades at a trailing P/E ratio of 18.4. That multiple sits in a zone often applied to large-cap health insurers: not as cheap as a deep-value name, but below the premium valuations usually reserved for faster-growing health-services providers. The 2.5% net margin underscores that profitability in this industry is measured in basis points across millions of members rather than wide unit margins. The 11.6% ROE indicates the balance sheet and capital structure are producing low-double-digit equity returns, which supports reinvestment and shareholder returns but is not unusually high historically for the sector.

The equity also displays defensive characteristics. The beta is 0.71, meaning the stock has historically moved less than the broad market, a pattern common among insurers with recurring premium revenue and government-backed programs. The current price is around $431.39, with a 50-day exponential moving average of $411.39 and an RSI of 58.9, leaving it neither deeply oversold nor strongly overbought on this intermediate-term measure.

Strategic priorities & outlook

Elevance’s 10-K sets out several operational priorities that define how it intends to run the business. The company wants to continue promoting value-based payment models that align incentives across patients, providers and payers, with the stated goal of delivering care in the right setting at the right time. It also plans to rationalize its portfolio of businesses and products, directing investment toward core operations and higher-growth capabilities and services. On the distribution and service side, management is emphasizing technology and advanced tools to improve interactions with customers, providers, brokers, agents and employees, including clinical coordination and administrative efficiency. Finally, the insurer aims to maintain market-competitive value while achieving what it calls “appropriate profitability” across customer segments.

Two operational facts in the filing carry meaningful investment context. First, U.S. government agencies accounted for approximately 32% of total consolidated revenues in 2025, with most of that flowing through the Health Benefits segment. That makes federal and state reimbursement decisions an important variable for revenue stability. Second, Elevance’s Blue Cross and Blue Shield license footprint gives it a brand and network position in the markets where it operates, but it also means the company’s strategy is partly shaped by the broader Blue system’s pricing, provider relationships and regulatory standing.

Macro & geopolitical exposure

As a Medical – Healthcare Plans company, Elevance is exposed first and foremost to U.S. healthcare regulation and reimbursement policy. Federal programs such as Medicare and Medicaid, along with Affordable Care Act exchange markets, determine pricing and eligibility for meaningful portions of its membership. Because roughly one-third of revenue comes from government agencies, changes in Medicare Advantage benchmark rates, Medicaid expansion or contraction, and exchange subsidy rules can directly affect revenue and margin. Centrally negotiated prescription drug policy and any expansion of government price-setting authority also matter to the CarelonRx and CarelonServices businesses.

Beyond regulation, the broader economy influences the employer-sponsored risk and self-funded books through employment levels and wage trends. Medical cost inflation is a persistent factor: if hospital, physician or pharmaceutical costs rise faster than premium pricing can capture, margins compress. Currency and overseas trade are not major operational considerations for a domestically focused health insurer, but interest rates influence investment income on the company’s float and reserves. Cybersecurity and operational disruptions are also sector-wide concerns, because claims processing and member data systems are critical infrastructure for any insurer.

Recent developments

The most recent news flow around Elevance has centered on option-market activity, insider transactions and relative-value comparisons. On October 26, 2026, Zacks reported that implied volatility was surging for Elevance Health stock options, a sign that the options market was pricing in a larger-than-usual expected move around an event—likely the approaching earnings report. On October 25, 2026, Defense World reported that hedge fund Iridian Asset Management had reduced its ELV holding and that insider Mark Kaye sold 10,584 shares. Insider and institutional sales are factual filings worth monitoring, though they can reflect portfolio rebalancing or personal liquidity needs as much as a directional view on the company. Earlier, on October 23, 2026, Zacks published a comparison of ELV versus RVTY asking which stock was the better value option, reflecting ongoing analyst debate about relative valuation in the healthcare services space.

Earnings behavior & post-earnings drift

Elevance has delivered a strong earnings track record over the last eight quarters, beating analyst estimates in seven of those eight reports for an 88% beat rate. The average earnings surprise across that span has been 15%, so the company has generally reported comfortably above the official consensus. The average 5-day price move following those reports is 4.69%, with the post-earnings drift classified as “up,” suggesting that positive results have typically leaked into the share price over the week after the release rather than being fully priced in overnight.

The most recent quarters show that pattern is not uniform. On October 21, 2026, Elevance reported actual EPS of $6.99 against an estimate of $4.71, a 48.4% surprise, and the stock rose 2.57% the next day but recorded a null 5-day change. On July 15, 2026, EPS came in at $7.45 versus $6.21 (a 20.0% beat), yet the stock fell 4.48% the next day and drifted down 0.32% over the following five sessions. The April 22, 2026 report was the strongest post-earnings performance: EPS of $12.58 beat the $10.82 estimate by 16.3%, producing a 5.51% one-day gain and a 14.76% rally over the next five trading days. By contrast, the January 28, 2026 report showed a 7.4% beat ($3.33 versus $3.10) and a modest 1.50% next-day rise but a 0.37% decline over the following five days. The next scheduled report is January 27, 2027 before the market open, with the consensus EPS estimate at $2.10.

For a deeper dive into consensus estimates, recent ratings changes and the broader institutional view, consider reviewing the full institutional verdict on Elevance Health.